The abstract is read at the publisher; the summary is JClub's.
In a mouse model of surgical menopause, estrogen deficiency increases retinal ganglion cell loss by ~60% and worsens functional recovery after ischemia-reperfusion injury.
- Why it matters: Declining estrogens with age is linked to neurodegeneration, but how estrogen loss changes neuronal resilience and which pathways can be co-targeted remains unclear.
- What they did: Mice (total N = 62; groups of 4–6) received selective estrogen receptor signaling or Fas pathway inhibition alone, or combined Raloxifene with the Fas receptor antagonist KP7-6; ex vivo retinal explants (N = 15) tested dual pathway effects.
- The result: Combined Raloxifene plus KP7-6 synergistically reduced RGC somatic loss to 18% and restored stratified retinal function near physiological levels in both ovariectomized and non-ovariectomized animals, with ex vivo data showing a 2-fold rise in neuronal survival and reduced cytotoxicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.